Physician profile
Nehal Desai
NPI 1801855622
$4,460.50
in general payments reported to CMS, 2019-2025
37 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $206 · 2021: $22.40 · 2022: $821 · 2023: $991 · 2024: $534 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $497.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $463.60 | 2019-2025 | |
| Lilly USA, LLC | $381.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $368.70 | 2019-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $355.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $302.85 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $228.14 | 2020-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.76 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $192.39 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $183.86 | 2019-2023 | |
| Exact Sciences Corporation | $138.10 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $92.02 | 2019-2025 | Spravato |
| Xeris Pharmaceuticals, INC. | $81.59 | 2022-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.41 | 2023-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $77.42 | 2024-2025 | Korlym |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $74.56 | 2022 | |
| Edwards Lifesciences Corporation | $69.39 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Daiichi Sankyo INC. | $65.54 | 2023-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $64.74 | 2020-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Vertex Pharmaceuticals Incorporated | $61.03 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.03 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $52.80 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $45.93 | 2020-2023 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $37.09 | 2025 | |
| Glaxosmithkline, LLC. | $36.84 | 2023-2025 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $34.74 | 2023-2025 | Nexletol |
| Currax Pharmaceuticals LLC | $28.52 | 2022 | |
| Dynavax Technologies Corporation | $26.55 | 2023 | Heplisav-B |
| Inari Medical, INC. | $21.84 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $19.04 | 2025 | Clottriever Bold Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $18.66 | 2023 | |
| Insulet Corporation | $16.93 | 2020 | |
| Astellas Pharma US INC | $14.88 | 2019 | |
| Mannkind Corporation | $14.84 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.88 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.37 | 2020 | |
| Shire North American Group INC | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nehal Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.